Dorsey Wright & Associates raised its stake in Edwards Lifesciences Corp. (NYSE:EW) by 5.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 42,400 shares of the medical research company’s stock after buying an additional 2,369 shares during the period. Edwards Lifesciences Corp. accounts for about 2.4% of Dorsey Wright & Associates’ portfolio, making the stock its 14th largest position. Dorsey Wright & Associates’ holdings in Edwards Lifesciences Corp. were worth $5,112,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Edwards Lifesciences Corp. by 0.7% in the second quarter. Vanguard Group Inc. now owns 18,796,184 shares of the medical research company’s stock valued at $1,874,543,000 after buying an additional 134,432 shares during the last quarter. FMR LLC boosted its stake in Edwards Lifesciences Corp. by 1.2% in the second quarter. FMR LLC now owns 12,366,588 shares of the medical research company’s stock valued at $1,233,319,000 after buying an additional 141,713 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Edwards Lifesciences Corp. by 62.3% in the second quarter. Ameriprise Financial Inc. now owns 4,253,976 shares of the medical research company’s stock valued at $424,200,000 after buying an additional 1,632,567 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Edwards Lifesciences Corp. by 4.6% in the second quarter. BlackRock Fund Advisors now owns 4,194,236 shares of the medical research company’s stock valued at $418,291,000 after buying an additional 184,872 shares during the last quarter. Finally, Janus Capital Management LLC boosted its stake in Edwards Lifesciences Corp. by 17.2% in the second quarter. Janus Capital Management LLC now owns 2,298,362 shares of the medical research company’s stock valued at $229,216,000 after buying an additional 337,788 shares during the last quarter. 83.52% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Edwards Lifesciences Corp. (NYSE:EW)

Edwards Lifesciences Corp. (NYSE:EW) traded down 1.86% on Friday, hitting $89.03. 1,716,208 shares of the company’s stock traded hands. The stock has a market cap of $19.04 billion, a PE ratio of 35.19 and a beta of 0.71. Edwards Lifesciences Corp. has a one year low of $72.20 and a one year high of $121.75. The stock has a 50-day moving average of $105.57 and a 200-day moving average of $107.33.

Edwards Lifesciences Corp. (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 25th. The medical research company reported $0.68 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.68. The business earned $739.40 million during the quarter, compared to analysts’ expectations of $749.14 million. Edwards Lifesciences Corp. had a net margin of 19.24% and a return on equity of 24.32%. The business’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter last year, the company posted $0.54 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Corp. will post $2.88 earnings per share for the current fiscal year.

Several analysts have weighed in on the company. Jefferies Group reaffirmed a “buy” rating and set a $125.00 price objective on shares of Edwards Lifesciences Corp. in a research report on Wednesday, July 27th. Zacks Investment Research cut Edwards Lifesciences Corp. from a “buy” rating to a “hold” rating in a research report on Friday, October 28th. BMO Capital Markets reaffirmed a “buy” rating and set a $120.00 price objective on shares of Edwards Lifesciences Corp. in a research report on Wednesday, July 27th. RBC Capital Markets reaffirmed an “outperform” rating and set a $123.00 price objective (down from $130.00) on shares of Edwards Lifesciences Corp. in a research report on Wednesday, October 26th. Finally, Citigroup Inc. lifted their target price on shares of Edwards Lifesciences Corp. from $86.00 to $94.00 and gave the company a “sell” rating in a report on Wednesday, July 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $117.68.

In related news, VP Donald E. Bobo, Jr. sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $90.13, for a total transaction of $1,351,950.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Huimin Wang sold 13,650 shares of the firm’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $115.72, for a total transaction of $1,579,578.00. The disclosure for this sale can be found here. Corporate insiders own 2.37% of the company’s stock.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related stocks with our FREE daily email newsletter.